Esperion(ESPR) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $168.4 million, a 144% increase year-over-year [15] - U.S. net product revenue was $43.7 million, up approximately 38% from $31.6 million in Q4 2024 [15] - Collaboration revenue surged to $124.7 million, a 232% increase driven by a one-time payment of $90 million from Otsuka [15] - The company ended 2025 with $167.9 million in cash and reduced debt by $55 million [14] Business Line Data and Key Metrics Changes - The U.S. bempedoic acid franchise saw strong prescription growth, with Q4 year-over-year sales increasing by 38% and retail prescription equivalents rising by 34% [5] - The number of unique healthcare practitioners prescribing NEXLETOL and NEXLIZET increased by nearly 25% [5] Market Data and Key Metrics Changes - Daiichi Sankyo Europe reported a 51% increase in fourth quarter royalty revenue compared to Q4 2024, expanding access to 30 countries [8] - The Japanese partner, Otsuka, successfully launched NEXLETOL in Japan, exceeding early market expectations [9] Company Strategy and Development Direction - The company introduced Vision 2040, outlining long-term ambitions and a roadmap for growth, including the acquisition of Corstasis Therapeutics [4] - The acquisition is expected to enhance the company's portfolio with Enbumyst, a first-in-class intranasal diuretic, and expand its presence in the cardiometabolic market [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued momentum into 2026, driven by strong reimbursement and favorable positioning in U.S. dyslipidemia guidelines [6] - The American College of Cardiology's recognition of the link between inflammation and cardiovascular disease is expected to support the use of bempedoic acid [6] Other Important Information - The company plans to fully leverage its commercial team's cardiovascular sales presence to scale adoption of Enbumyst and accelerate revenue contribution [12] - The transaction for the acquisition of Corstasis is expected to close in Q2 2026 [12] Q&A Session Summary Question: Capacity and next steps for Corstasis - Management confirmed they are ready for a full-scale launch and will provide updates on the auto-injector after the deal closes [20][24] Question: Updates on ACC guidelines - Management anticipates the guidelines will be released a week before the ACC conference and is preparing a comprehensive plan for outreach [28][30] Question: Impact of EU guidelines on U.S. prescribing - Management noted that the European guidelines have positively influenced U.S. prescribing and expects similar outcomes from the upcoming U.S. guidelines [40][42] Question: Triple combination product expectations - The triple combination therapy is expected to have high interest, with a focus on both statin intolerant patients and those requiring low-dose statins [60] Question: Corstasis clinical obligations - There are minimal post-market studies required for Enbumyst, which have been accounted for in the updated expense guidance [69] Question: Future sales force expansion - The sales team will expand modestly post-acquisition to ensure coverage of key settings, including heart failure clinics [39]